Pages that link to "Q78418481"
Jump to navigation
Jump to search
The following pages link to Lipiarmycin, a new antibiotic from Actinoplanes. II. Isolation, chemical, bilogical and biochemical characterization. (Q78418481):
Displaying 50 items.
- GE23077 binds to the RNA polymerase 'i' and 'i+1' sites and prevents the binding of initiating nucleotides (Q21128776) (← links)
- New target for inhibition of bacterial RNA polymerase: 'switch region' (Q24634933) (← links)
- In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile (Q33743827) (← links)
- Inhibition by lipiarmycin of bacteriophage growth in Bacillus subtilis (Q33915776) (← links)
- Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections (Q34030436) (← links)
- Genetics of antibiotic production (Q34073561) (← links)
- Antibiotics in the clinical pipeline in 2011. (Q34185670) (← links)
- Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection (Q34276090) (← links)
- Actinoplanes lichenis sp. nov., isolated from lichen (Q34501158) (← links)
- Natural products to drugs: natural product-derived compounds in clinical trials (Q34780898) (← links)
- Sources for Leads: Natural Products and Libraries (Q35789059) (← links)
- Fidaxomicin--the new drug for Clostridium difficile infection (Q35877773) (← links)
- In vitro activities of different inhibitors of bacterial transcription against Staphylococcus epidermidis biofilm (Q36094834) (← links)
- Astonishing diversity of natural surfactants: 2. Polyether glycosidic ionophores and macrocyclic glycosides (Q36163711) (← links)
- Natural products--the future scaffolds for novel antibiotics? (Q36313566) (← links)
- Lipiarmycin-resistant ribonucleic acid polymerase mutants of Bacillus subtilis (Q36413967) (← links)
- Bacterial Transcription as a Target for Antibacterial Drug Development. (Q36631410) (← links)
- Progress in targeting bacterial transcription (Q36748850) (← links)
- Emerging therapies for Clostridium difficile infection - focus on fidaxomicin (Q36984883) (← links)
- Mother Nature's gifts to diseases of man: the impact of natural products on anti-infective, anticholestemics and anticancer drug discovery. (Q37034015) (← links)
- Bacterial RNA polymerase inhibitors: an organized overview of their structure, derivatives, biological activity and current clinical development status (Q37387373) (← links)
- Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance (Q37588248) (← links)
- Sources of novel antibiotics--aside the common roads (Q37791857) (← links)
- Fidaxomicin: first-in-class macrocyclic antibiotic (Q37910246) (← links)
- Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection (Q37966763) (← links)
- Fidaxomicin, a new treatment for Clostridium difficile infections (Q37989945) (← links)
- From natural product to marketed drug: the tiacumicin odyssey (Q38056625) (← links)
- Antibiotics in the clinical pipeline in 2013. (Q38133967) (← links)
- Inhibitors of bacterial transcription are compounds for potent antimicrobial drugs (Q38210261) (← links)
- Growing the seeds sown by Piero Sensi (Q38239458) (← links)
- Natural product and natural product derived drugs in clinical trials. (Q38247457) (← links)
- Antibacterials Developed to Target a Single Organism: Mechanisms and Frequencies of Reduced Susceptibility to the Novel Anti-Clostridium difficile Compounds Fidaxomicin and LFF571. (Q38719092) (← links)
- A new spanner in the works of bacterial transcription (Q38873502) (← links)
- Recent developments in natural product-based drug discovery for tuberculosis (Q39021653) (← links)
- Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis (Q39152809) (← links)
- Initiation of transcription in vitro is inhibited by lipiarmycin (Q39650398) (← links)
- Members of the Genus Actinoplanes and their Antibiotics (Q39811457) (← links)
- Mechanistic aspects of promoter binding and chain initiation by RNA polymerase (Q40247557) (← links)
- Total Synthesis of the Glycosylated Macrolide Antibiotic Fidaxomicin (Q41130957) (← links)
- Safety and efficacy of fidaxomicin in the treatment of Clostridium difficile-associated diarrhea (Q41415171) (← links)
- Total synthesis of the tiacumicin B (lipiarmycin A3/fidaxomicin) aglycone (Q41598094) (← links)
- Total synthesis of the protected aglycon of fidaxomicin (tiacumicin B, lipiarmycin A3). (Q41644940) (← links)
- Final Demonstration of the Co-Identity of Lipiarmycin A3 and Tiacumicin B (Fidaxomicin) through Single Crystal X-ray Analysis. (Q41860568) (← links)
- The transcription inhibitor lipiarmycin blocks DNA fitting into the RNA polymerase catalytic site (Q42118811) (← links)
- Actinomycetes: still a source of novel antibiotics (Q46319269) (← links)
- Study of the Construction of the Tiacumicin B Aglycone. (Q48088991) (← links)
- Natural Products as Platforms To Overcome Antibiotic Resistance (Q48281604) (← links)
- Structural Basis of Transcription Inhibition by Fidaxomicin (Lipiarmycin A3). (Q52335118) (← links)
- Characterization of a Sugar-O-methyltransferase TiaS5 Affords New Tiacumicin Analogues with Improved Antibacterial Properties and Reveals Substrate Promiscuity (Q58339057) (← links)
- Characterization of Tiacumicin B Biosynthetic Gene Cluster Affording Diversified Tiacumicin Analogues and Revealing a Tailoring Dihalogenase (Q58339058) (← links)